Korean J Gastroenterol.  2011 Dec;58(6):364-366. 10.4166/kjg.2011.58.6.364.

Could HBsAg Quantification Predict Sustained Response Following Antiviral Therapy for Chronic Hepatitis B?

• Han CJ

• KMID: 1043339
• DOI: http://doi.org/10.4166/kjg.2011.58.6.364

Abstract

No abstract available.

Reference

References

1. Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut. 2003; 52:1779–1783.

2. Ryu SH, Chung YH, Choi MH, et al. Longterm additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol. 2003; 39:614–619.

3. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005; 42:302–308.

4. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005; 128:1890–1897.

5. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004; 126:1750–1758.

6. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007; 5:1462–1468.

7. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAgnegative patients. Hepatology. 2009; 49:1151–1157.

8. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAgnegative chronic hepatitis B. Hepatology. 2009; 49:1141–1150.

9. Kohmoto M, Enomoto M, Tamori A, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent micro-particle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol. 2005; 75:235–239.

10. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatmentrelated HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther. 2007; 12:73–82.

11. Wiegand J, Wedemeyer H, Finger A, et al. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther. 2008; 13:547–554.

12. Borgniet O, Parvaz P, Bouix C, et al. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol. 2009; 81:1336–1342.

13. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010; 52:1611–1620.

14. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011; 54:449–454.

15. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report. J Hepatol. 2011; 55:1121–1131.

16. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol. 2010; 52:475–477.

17. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009; 3(Suppl 1):S5–S15.